Literature DB >> 12779093

Serum potassium in the crush syndrome victims of the Marmara disaster.

M S Sever1, E Erek, R Vanholder, G Kantarci, M Yavuz, A Turkmen, H Ergin, M Y Tulbek, M Duranay, G Manga, S Sevinir, N Lameire.   

Abstract

BACKGROUND: Hyperkalemia is a major cause of mortality in the patients who suffer from crush syndrome in the aftermath of major earthquakes. The aim of this study is to investigate the frequency and effects of hyperkalemia in the 639 victims of catastrophic Marmara earthquake that struck northwestern Turkey, in August 1999. PATIENTS AND METHODS: Within the first week of disaster, questionnaires were sent to 35 reference hospitals that treated the victims. Information on serum potassium which was provided in 595 out of 639 questionnaires was submitted to analysis.
RESULTS: In the patients who were admitted within the first 3 days of the disaster (n = 401) serum potassium was 5.4 +/- 1.3 mEq/l, which was higher than in those admitted thereafter (n = 171) (4.5 +/- 1.1 mEq/l) (p = 0.02). Considering the whole series, males (p = 0.01), patients needing dialysis support (p < 0.001) and non-survivors (p = 0.001) were characterized by higher serum potassium at admission. Seventy patients' serum potassium was above 7 mEq/l, while 22 patients were hypokalemic (< 3.5 mEq/l). Admission potassium correlated with many clinical and laboratory variables indicating the severity of the trauma, and a logistic regression model with clinical and laboratory parameters upon admission, revealed potassium as the most significant predictor of dialysis needs in the victims admitted within the first 3 days (p = 0.008, OR = 3.33). Among the victims who were admitted to hospitals 1 week after the disaster, 8 had serum potassium levels above 6.5 mEq/l; among 4 of them were complicated by hyperkalemia even higher than 7.5 mEq/l. These findings undeline the importance of hyperkalemia during clinical course.
CONCLUSION: The most important and fatal medical complication in crush syndrome patients is hyperkalemia. Risk of fatal hyperkalemia continues even after hospitalization. Empirical therapy at the scene is indicated especially in male victims with severe soft tissue traumas. Early detection and treatment of hyperkalemia may improve the final outcome of renal disaster victims.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12779093     DOI: 10.5414/cnp59326

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

1.  Bicarbonate promotes BK-α/β4-mediated K excretion in the renal distal nephron.

Authors:  Ryan J Cornelius; Donghai Wen; Lori I Hatcher; Steven C Sansom
Journal:  Am J Physiol Renal Physiol       Date:  2012-09-19

2.  Crush Injuries and the Crush Syndrome.

Authors:  S Rajagopalan
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Management of crush syndrome casualties after disasters.

Authors:  Mehmet Sukru Sever; Raymond Vanholder
Journal:  Rambam Maimonides Med J       Date:  2011-04-30

4.  Disaster nephrology: a new concept for an old problem.

Authors:  Mehmet Sukru Sever; Norbert Lameire; Wim Van Biesen; Raymond Vanholder
Journal:  Clin Kidney J       Date:  2015-04-26

5.  Rhabdomyolysis in Earthquake Victims in Nepal.

Authors:  Rabin Nepali; Mahesh Raj Sigdel; Dibya Singh Shah
Journal:  Kidney Int Rep       Date:  2016-12-09

6.  Anisodamine Ameliorates Hyperkalemia during Crush Syndrome through Estradiol-Induced Enhancement of Insulin Sensitivity.

Authors:  Jian-Guang Yu; Bo-Shi Fan; Jin-Min Guo; Yun-Jie Shen; Ye-Yan Hu; Xia Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

7.  Excitation-induced exchange of Na+, K+, and Cl- in rat EDL muscle in vitro and in vivo: physiology and pathophysiology.

Authors:  Torben Clausen
Journal:  J Gen Physiol       Date:  2013-01-14       Impact factor: 4.086

8.  20-Day Trend of Serum Potassium Changes in Bam Earthquake Victims with Crush Syndrome; a Cross-sectional Study.

Authors:  Saeed Safari; Iraj Najafi; Mostafa Hosseini; Alireza Baratloo; Mahmoud Yousefifard; Hamidreza Mohammadi
Journal:  Emerg (Tehran)       Date:  2017-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.